Skip to main content
construction release_alert
Scholars@Duke will be undergoing maintenance April 11-15. Some features may be unavailable during this time.
cancel
Journal cover image

C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.

Publication ,  Journal Article
Jaffe, GJ; Westby, K; Csaky, KG; Monés, J; Pearlman, JA; Patel, SS; Joondeph, BC; Randolph, J; Masonson, H; Rezaei, KA
Published in: Ophthalmology
April 2021

PURPOSE: The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). DESIGN: International, prospective, randomized, double-masked, sham-controlled, pivotal phase 2/3 clinical trial. PARTICIPANTS: A total of 286 participants with GA secondary to AMD. MAIN OUTCOME MEASURES: The primary efficacy endpoint was the mean rate of change in GA over 12 months measured by fundus autofluorescence (FAF) at 3 timepoints: baseline, month 6, and month 12. RESULTS: The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts. The results for both dose groups were statistically significant. Avacincaptad pegol was generally well tolerated after monthly administration over 12 months. There were no avacincaptad pegol-related adverse events (AEs) or inflammation. Further, there were no ocular serious AEs (SAEs) and no cases of endophthalmitis. The most frequent ocular AEs were related to the injection procedure. CONCLUSIONS: Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12-month period. Because C5 inhibition theoretically preserves C3 activity, it may offer additional safety advantages. A second confirmatory pivotal clinical trial is underway to confirm the efficacy and safety of avacincaptad pegol in slowing the GA growth (GATHER2 Study).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Ophthalmology

DOI

EISSN

1549-4713

Publication Date

April 2021

Volume

128

Issue

4

Start / End Page

576 / 586

Location

United States

Related Subject Headings

  • Visual Acuity
  • Prospective Studies
  • Ophthalmology & Optometry
  • Male
  • Macular Degeneration
  • Intravitreal Injections
  • Humans
  • Geographic Atrophy
  • Follow-Up Studies
  • Fluorescein Angiography
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Jaffe, G. J., Westby, K., Csaky, K. G., Monés, J., Pearlman, J. A., Patel, S. S., … Rezaei, K. A. (2021). C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology, 128(4), 576–586. https://doi.org/10.1016/j.ophtha.2020.08.027
Jaffe, Glenn J., Keith Westby, Karl G. Csaky, Jordi Monés, Joel A. Pearlman, Sunil S. Patel, Brian C. Joondeph, John Randolph, Harvey Masonson, and Kourous A. Rezaei. “C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Ophthalmology 128, no. 4 (April 2021): 576–86. https://doi.org/10.1016/j.ophtha.2020.08.027.
Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, et al. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576–86.
Jaffe, Glenn J., et al. “C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial.Ophthalmology, vol. 128, no. 4, Apr. 2021, pp. 576–86. Pubmed, doi:10.1016/j.ophtha.2020.08.027.
Jaffe GJ, Westby K, Csaky KG, Monés J, Pearlman JA, Patel SS, Joondeph BC, Randolph J, Masonson H, Rezaei KA. C5 Inhibitor Avacincaptad Pegol for Geographic Atrophy Due to Age-Related Macular Degeneration: A Randomized Pivotal Phase 2/3 Trial. Ophthalmology. 2021 Apr;128(4):576–586.
Journal cover image

Published In

Ophthalmology

DOI

EISSN

1549-4713

Publication Date

April 2021

Volume

128

Issue

4

Start / End Page

576 / 586

Location

United States

Related Subject Headings

  • Visual Acuity
  • Prospective Studies
  • Ophthalmology & Optometry
  • Male
  • Macular Degeneration
  • Intravitreal Injections
  • Humans
  • Geographic Atrophy
  • Follow-Up Studies
  • Fluorescein Angiography